RecruitingNCT03296826
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Enrollment
600 participants
Start Date
Nov 8, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.
Eligibility
Sex: FEMALEMin Age: 20 Years
Plain Language Summary
Simplified for easier understanding
This study is tracking women who carry BRCA1 or BRCA2 gene mutations — genes linked to higher risk of ovarian and breast cancer — to better understand their health outcomes over time.
**You may be eligible if...**
- You are a woman with a BRCA1 or BRCA2 gene mutation (or both), or an uncertain gene change called a variant of uncertain significance (VUS)
- You have already received genetic counseling at a medical facility
- You are 20 years old or older
- You are willing to give written consent to participate
**You may NOT be eligible if...**
- You currently have ovarian or fallopian tube cancer
- You have a past diagnosis of ovarian, fallopian tube, or peritoneal (abdominal lining) cancer
- The study doctor decides participation is not appropriate for you
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03296826
Related Trials
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
NCT063214842 locations
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589837 locations
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
NCT072821581 location
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT0498111916 locations
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
NCT076177531 location